Geode Capital Management LLC Boosts Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Geode Capital Management LLC raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,389,240 shares of the company’s stock after acquiring an additional 45,930 shares during the period. Geode Capital Management LLC’s holdings in Intellia Therapeutics were worth $27,865,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in NTLA. Whipplewood Advisors LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth $40,000. Jones Financial Companies Lllp raised its position in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock valued at $60,000 after acquiring an additional 2,299 shares in the last quarter. KBC Group NV boosted its stake in shares of Intellia Therapeutics by 62.4% during the 4th quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after purchasing an additional 2,340 shares during the last quarter. Finally, AdvisorNet Financial Inc boosted its position in Intellia Therapeutics by 96.4% during the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after acquiring an additional 4,950 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. BMO Capital Markets lowered their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. The Goldman Sachs Group restated a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Wedbush restated a “neutral” rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Finally, Truist Financial cut their target price on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Price Performance

NTLA stock opened at $7.23 on Friday. The company’s 50 day simple moving average is $8.93 and its 200-day simple moving average is $12.28. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18. The firm has a market capitalization of $748.43 million, a P/E ratio of -1.33 and a beta of 2.23.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.